Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Year ended March 31, 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Audited Financial Results
Audit Opinion:
Unmodified opinion (clean) with Emphasis of Matter regarding GST disputes
Key Financial Highlights [INR in Lakhs]:
Consolidated Results:
For Year Ended March 31, 2026:
- Revenue from Operations: ₹15,061.74 (vs. ₹14,585.70 in FY25, +3.3% YoY)
- Total Income: ₹15,537.37 (vs. ₹14,859.92 in FY25)
- Net Profit: ₹1,109.98 (vs. ₹415.25 in FY25, +167% YoY)
- EPS: ₹4.69 (Basic and Diluted) (vs. ₹1.76 in FY25)
- Other Equity: ₹7,249.32 (vs. ₹6,115.02 in FY25)
For Quarter Ended March 31, 2026:
- Revenue from Operations: ₹4,223.93 (vs. ₹3,906.00 in Q4 FY25, +8.1% YoY)
- Total Income: ₹4,400.09 (vs. ₹4,008.50 in Q4 FY25)
- Net Profit: ₹274.91 (vs. ₹131.10 in Q4 FY25, +110% YoY)
- EPS: ₹1.16 (Basic and Diluted) (vs. ₹0.55 in Q4 FY25)
Standalone Results:
Not Specified
Segment-wise Performance:
The company operates in only one segment: manufacturing of pharmaceutical formulations, as per Ind AS 108.
Balance Sheet Highlights (as of March 31, 2026):
- Paid-up Share Capital: ₹2,365.63 Lakhs (Face Value ₹10 each)
- Cash and Cash Equivalents: ₹202.45 Lakhs
- Total Assets: ₹17,553.24 Lakhs
- Total Borrowings (Current + Non-current): ₹1,132.54 Lakhs (Current) + ₹1,778.22 Lakhs (Non-current) = ₹2,910.76 Lakhs
Cash Flow Statement Highlights (FY26):
- Net Cash from Operating Activities: ₹1,537.08 Lakhs
- Net Cash used in Investing Activities: ₹(2,240.10) Lakhs
- Net Cash from Financing Activities: ₹562.24 Lakhs
- Net Decrease in Cash: ₹(140.81) Lakhs
Corporate Actions:
Not Specified
Other Significant Information:
- The financial results were reviewed by the Audit Committee on May 20, 2026
- Figures for quarters are balancing figures between audited full year and published unaudited nine months figures
- Change in accounting policy: Not Specified
- Forward-looking guidance: Not Specified